Timber Pharmaceuticals Inc (TMBR) Stock
TMBR is no longer traded. Timber Pharmaceuticals was delisted from the NYSE American in March 2024.
Prices on this page are historical; the last trade was March 19, 2024 at $0.00.
Timber Pharmaceuticals stock price history
TMBR final trading statistics
- Final close
- $0.00
- Final trading day
- Mar 19, 2024
- Market cap at delisting
- $1.18M
- Shares outstanding
- 3.43M
- Final 52-week range
- $0.00 – $3.36
- Avg. volume (final 3 mo.)
- 4,199
- All-time high (split-adj.)
- $1000000.00 · Apr 2014
- All-time low (split-adj.)
- $0.00 · Mar 2024
- Return since IPO
- -100.0%
- Beta
- -0.65
- Book value / share
- -$0.86
- Price / book
- -0.00
Timber Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $83.2K | -$19.4M | -$13.24 |
| FY2021 | $295.7K | -$10.6M | -$2.78 |
| FY2020 | $453.8K | -$15.1M | -$68.30 |
| FY2019 | $324.6K | -$3.7M | -$495.36 |
| FY2018 | $57.0K | -$17.3M | -$3900.00 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Timber Pharmaceuticals Inc
Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey. On November 17, 2023, Timber Pharmaceuticals, Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Timber Pharmaceuticals stock FAQ
What happened to Timber Pharmaceuticals stock?
Timber Pharmaceuticals stock was delisted from the NYSE American. Its final close was $0.00 on March 19, 2024.
Is TMBR stock still trading?
No. TMBR was delisted from the NYSE American in March 2024 and no longer trades on a U.S. exchange.
What was the last price of TMBR stock?
TMBR closed at $0.00 on its final trading day, March 19, 2024, for a market value of about $1.18M.
What were Timber Pharmaceuticals's revenue and earnings in its last full fiscal year?
Timber Pharmaceuticals reported revenue of $83.2K and net income of -$19.4M in fiscal 2022, its last full year as a public company.
When did Timber Pharmaceuticals go public?
Timber Pharmaceuticals Inc stock began trading on June 9, 2015.